Ocugen is developing a COVID-19 vaccine in the US and India as I type. It's into gene therapy. The market cap is just under U$1.5 billion.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat blindness diseases. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many”. And our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy.
Notice the explosion in prices for both. Round 2 has started for OCGN. For SVA, we're all waiting for "Round 2"... Coming to a stock ticker near you "soon-ish".
This is a two year chart to get the shapes (First: SVA vs OCGN; Second: OCGN vs SVA):
This is a One Year Chart (First: SVA vs OCGN; Second: OCGN vs SVA):